Sage (SAGE) is reportedly suing Biogen (BIIB) over enforcement of a standstill agreement in the wake of an unsolicited ...

In a report released today, David Amsellem from Piper Sandler reiterated a Hold rating on Biogen (BIIB – Research Report), with a price target ...

Check the time stamp on this data. Updated AI-Generated Signals for Biogen Inc. (BIIB) available here: BIIB. Type a few ...

ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth quarter 2024 ...

Biogen (BIIB) and Eisai's (ESALF) (ESAIY) announce that U.S. FDA agreed to review their subcutaneous form of Alzheimer's ...

Piper Sandler analyst David Amsellem reiterated a Hold rating on Biogen (BIIB – Research Report) today and set a price target of $138.00. The ...

On Monday, the FDA accepted Eisai Co., Ltd. (OTC:ESALY) and Biogen Inc’s (NASDAQ:BIIB) Biologics License Application (BLA) ...

Biogen Inc. (BIIB), headquartered in Cambridge, Massachusetts, specializes in discovering, developing, manufacturing, and ...

Shares of Biogen Inc. BIIB shed 1.44% to $141.00 Wednesday, on what proved to be an all-around positive trading session for ...

Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional ...

The pharmaceutical industry, grappling with new government limits on drug prices, is focusing its requests for ...

The biotech industry is booming thanks to the rising demand for personalized medicine, investment in innovations, and ongoing ...